ReviewCurrent atherosclerosis reports2026

Combination cardiometabolic therapy in type 2 diabetes: optimizing SGLT2 inhibitor and GLP‑1 receptor agonist use.

Laura R Porterfield et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.